LigandPro platform identifies novel small molecule "hits" that can be built into TPD drugs.  It offers an efficient and cost-effective approach to drug discovery compared to traditional biochemical High Throughput Screening (HTS). It can also serve as a complement to other experimental and in-silico methods.

Unbiased Screening

LigandPro utilizes a protein agnostic approach, it doesn't rely on preconceived hypotheses about protein interactions, allowing for the identification of novel interactions

Comprehensive Polypharmocology

LigandPro generates a detailed protein-small molecule interaction map, providing valuable insights into potential drug targets and their mechanisms of action reducing the likelihood of off-target impacts

Complementary

While LigandPro can be used as a standalone platform, it is particularly powerful when combined with other computational and experimental techniques:

• Integration with structure-based methods: LigandPro's ligand-based approach can be used in conjunction with structure-based virtual screening to improve their hit rates
• Refinement of HTS results: It can help prioritize and validate hits from traditional HTS efforts
• Target prediction: LigandPro can assist in identifying potential off-target interactions for lead compounds

Enhanced Sensitivity

The platform's unique screening process, allows for the detection of even transient and low-affinity interactions. This sensitivity is crucial for uncovering potential drug targets that might be missed by other screening methods

Cost-Effectiveness and Speed

LigandPro is designed to utilize smaller quantities of compounds, less expensive reagents and instrumentation requirements while delivering higher throughput. In addition, by targeting any protein surface, we can reduce the need for downstream research. Through a combination of these approaches, we are able to complete screening projects in 3-6 months and at less than 50% of the cost of traditional approaches

Versatile

LigandPro can be applied to various stages of the drug discovery pipeline:

• Hit identification: Screening large compound libraries to find initial hits
• Lead optimization: Guiding the modification of lead compounds to improve potency and selectivity
• Drug repurposing: Identifying new therapeutic applications for existing drugs